Abstract
Background/Aim: The long-term administration of proton pump inhibitors (PPIs) is useful for preventing recurrent reflux esophagitis. On the other hand, several adverse reactions, such as an increase in the blood gastrin level, have been reported. The aim of the present study was to examine the increase in the blood gastrin level due to the long-term administration of conventional PPIs compared with vonoprazan. Methods: A prospective cross-sectional study was conducted. We examined the blood gastrin levels of patients taking vonoprazan or conventional PPIs in whom the grade of atrophic gastritis had been endoscopically evaluated in the last year. Results: The blood gastrin level was significantly higher in the vonoprazan group than that in the PPI group in patients with milder or no atrophic gastritis, irrespective of the administration periods. However, no significant difference was observed between the groups in patients with severe atrophic gastritis. Conclusion: Vonoprazan more markedly increased the blood gastrin level compared with conventional PPIs in patients with milder or no atrophic gastritis. This indicates that vonoprazan may have stronger acid-suppressing effects in such patients than conventional PPIs. Key Message: We should be aware of the potential development of hypergastrinemia during the long-term administration of vonoprazan, especially in patients with mild or no atrophic gastritis.
Journal Section:
Original Paper
References
1.
Sugano K, Kinoshita Y, Miwa H, et al: Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients. Aliment Pharmacol Ther 2012; 36: 115–125.
[PubMed]
2.
Sugano K, Choi MG, Lin JT, et al: Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut 2014; 63: 1061–1068.
[PubMed]
3.
Havu N, Mattsson H, Ekman L, et al: Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long term administration of ranitidine. Digestion 1990; 45: 189–195.
[PubMed]
4.
Okuyama M, Nakahara K, Iwakura N, et al: Factors associated with potassium-competitive acid blocker non-response in patients with proton pump inhibitor refractory gastrointestinal esophageal disease. Digestion 2017; 95: 281–287.
[PubMed]
5.
Hoshino S, Kawami N, Takenouchi N, et al: Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 2017; 95: 156–161.
[PubMed]
6.
Yamashita H, Kanamori A, Kano C, et al: The effects of switching to Vonoprazan, a novel potassium-competitive acid blocker, on gastric acidity and reflux patterns in patients with erosive esophagitis refractory to proton pump inhibitors. Digestion 2017; 96: 52–59.
[PubMed]
7.
Tsujimae M, Yamashita H, Hashimura H, et al: A comparative study of a new class of Gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of Helicobacter pylori. Digestion 2016; 94: 240–246.
[PubMed]
8.
Ashida K, Sakurai Y, Hori T, et al: Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016; 43: 240–251.
[PubMed]
9.
Kimura K, Takemoto T: An endscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 3: 87–97.
10.
Kaltsas G, Grozinsky-Glasberg S, Alexandraki KI, et al: Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf) 2014; 81: 157–168.
[PubMed]
11.
Cockburn AN, Morgan CJ, Genta RM: Neuroendocrine proliferations of the stomach: a pragmatic approach for the perplexed pathologist. Adv Anat Pathol 2013; 20: 148–157.
[PubMed]
12.
Burkitt MD, Pritchard DM: Review article: pathogenesis and management of gastric carcinoid tumuors. Aliment Pharmacol Ther 2006; 24: 1305–1320.
[PubMed]
13.
Dockray GJ, Varro A, Dimaline R, et al: The gastrins: their production and biological activities. Annu Rev Physiol 2001; 63: 119–139.
[PubMed]
14.
Ohkusa T, Maekawa T, Arakawa T, et al: Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther 2005; 21: 1331–1339.
[PubMed]
15.
Fujimoto K, Hongo M; Maintenance Study Group: Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once dairy in Japanese patients with reflux esophagitis. Intern Med 2011; 50: 179–188.
[PubMed]
16.
Galmiche JP, Hatlebakk J, Attwood S, et al: Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305: 1969–1977.
[PubMed]
17.
Lundell L, Vieth M, Gibson F, et al: Systemic review: the effect of long-term proton pump inhibitor on serum gastrin level and gastric histology. Aliment Pharmacol Ther 2015; 42: 649–663.
[PubMed]
18.
Kagami T, Sahara S, Ichikawa H, et al: Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 2016; 43: 1048–1059.
[PubMed]
19.
Ohta Y: Quantitative study of gastric mucosal G-cell population in relation to pattern of atrophic gastritis. Gastroenterol Endosc 1981; 23: 1704–1721.
20.
Rao SS, Nayak KS, Swarnalata G, et al: Gastric carcinoid associated with ranitidine in a patient with renal failure. Am J gastroenterol 1993; 88: 1273–1274.
[PubMed]
21.
Haga Y, Nakatsura T, Shibata Y, et al: Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci 1998; 43: 253–257.
[PubMed]
22.
Dowson R, Manson JM: Omeprazole in oesophageal refhux disease. Lancet 2000; 356: 1770–1771.
[PubMed]
23.
Jianu, CS, Fossmark R, Viset T, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012; 36: 644–649.
[PubMed]
24.
Jianu, C.S, Lange OJ, Viset T, et al: Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012; 47: 64–67.
[PubMed]
25.
Lahner E, Pilozzi E, Esposito G, et al: Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge. Scand J Gastroenterol 2014; 49: 506–510.
[PubMed]
26.
Cavalcoli F, Zilli A, Conte D, et al: Gastric neuroendocrine neoplasms and proton pump inhibitor: fact or coincidence? Scand J Gastroenterol 2015; 50: 1397–1403.
[PubMed]
27.
Nandy N, Hanson JA, Strickland RG, et al: Solitary gastric carcinoid tumor associated with long-term use of omeprazole: a case report and review of the literature. Dig Dis Sci 2016; 61: 708–712.
[PubMed]
28.
Inada M: Meal-stimulated gastric acid secretion and gastrin release in patients with gastric or duodenal ulcer: a study by intragastric titration method. J Japanese Soc Gastroenterol 1984; 81: 2516–2525.
[PubMed]
29.
Hayashi S: Diurnal variations of peripheral blood gastrin level in gastrointestinal disorders. J Japanese Soc Gastroenterol 1978; 75: 807–817.
30.
Helgadottir H, Metz DC, Yang YX, et al: The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. Dig Liver Dis 2014; 46: 1251–1230.
[PubMed]
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.
